新辅助化疗后ER、PR阳性表达乳腺癌患者的内分泌治疗

Endocrine therapy for breast cancer patients with ER and PR turning positive after neoadjuvant chemotherapy

目的 探讨乳腺癌新辅助化疗后ER、PR阳性表达的乳腺癌患者内分泌治疗的疗效.方法 将97例术前ER、PR阴性表达经新辅助化疗后转变为阳性表达的乳腺癌患者分为两组（内分泌治疗组和对照组）进行治疗,并随访15～60个月,对其生存率和总生存率进行比较.结果 内分泌治疗组3年和5年无病生存率分别为74.5%（38/51）、60.7%（31/51）,其3年和5年总生存率为80.0%（41/51）、74.5%（38/51）.对照组的3年和5年无病生存率分别为54.2%（26/46）及41.7%（20/46）,3年和5年的总生存率为60.9%（28/46）、50%（23/46）.内分泌治疗组无病生存率及总生存率均高于对照组（P＜0.05）.结论 新辅助化疗后ER、PR变为阳性表达的患者应用内分泌治疗可提高此类患者的生存率.

Objective To explore the effect of endocrine therapy in breast cancer patients whose estrogen receptor （ER） and progesterone receptor（PR） was preoperatively negative and turned positive after neoadjuvant chemotherapy. Methods The clinical experimental study was carried out in 97 cases of breast cancer which were divided into endocrine treatment group and control group. The follow-up time ranged from 15 to 60 months. Results In endocrine treatment group, 3 and 5-year disease-free survival were respectively 74.5% （38/51）, 60.7% （31/51）, and 3 and 5-year overall survival were respectively 80%（41/51）, 74. 5% （38/51）. In control group, 3 and 5-year disease-free survival were respectively 54.2% （26/46）, 41.7%（20/46）, and 3 and 5-year overall survival were 60.9%（28/46）,50%（23/46）,respectively. The corresponding values were significantly higher in endocrine treatment group than in control group（P〈0.05）.Conclusions Remedy endocrine therapy improves the disease-free and overall survival rate in breast cancer patients with the expression of ER and PR turning positive after initial neoadjuvant chemotherapy.